Abstract
Background With TNF-blockers availability for spondyloarthritis (SpA), evaluation of new drugs requires quick “go/no go” signals in small scale, short term proof-of-concept (PoC) trials. Biomarkers complementing clinical evaluations may help reducing length and size of these PoCs. We aimed to identify and validate serum biomarkers to predict clinical response at group level in these trials. Methods Matrix metalloproteinase-3 (MMP-3), Pentraxin-3 (PTX3), high sensitive C-reactive protein (hs-CRP), calprotectin, Interleukin-6 (IL-6), Vascular Endothelial Growth Factor (VEGF), and alpha-2-macroglobulin (alpha-2-MG) were selected as biomarkers [1-3]. Serum levels were determined by ELISA in healthy controls (n=20) and at week 0 and 2 in SpA patients treated with infliximab (5 mg/kg; week 0, 2, and 6) (n=18) or placebo (n=19). Patient and physician global assessment of disease activity and BASDAI were evaluated at week 0 and 12. Results Baseline serum levels of PTX-3, hs-CRP, calprotectin and VEGF (all p<0.001) were increased in SpA compared to healthy controls, whereas no differences were observed for IL-6 and alpha-2-MG. Clinical evaluation at week 12 showed that infliximab but not placebo decreased disease activity (p<0.005). Accordingly biomarker levels remained stable in the placebo group. In contrast, a decrease of hsCRP (p<0.0001), calprotectin (p<0.001), and IL-6 (p =0.04) was observed two weeks after infliximab initiation, with a similar trend for MMP-3 (p=0.063). Other biomarker levels were not significantly modulated. The Standardized Response Mean (SRM), reflecting the predictive value at the group level, was high for calprotectin (SRM=1.259) and good for hs-CRP (SRM=0.746) and MMP-3 (SRM=0.521). At individual level, linear regression revealed low correlations of changes in hs-CRP (r 2 between 0.24 and 0.36) and calprotectin (r 2 between 0.08 and 0.19) at week 2 with clinical outcome parameters at week 12. Conclusion Early changes in serum calprotectin, hs-CRP, and MMP-3 showed a good ability to predict longer term clinical response in SpA at group level. These biomarkers are currently being validated in independent PoC trials.
Highlights
With TNF-blockers availability for spondyloarthritis (SpA), evaluation of new drugs requires quick “go/no go” signals in small scale, short term proof-of-concept (PoC) trials
Serum levels were determined by ELISA in healthy controls (n=20) and at week 0 and 2 in SpA patients treated with infliximab (5 mg/kg; week 0, 2, and 6) (n=18) or placebo (n=19)
Patient and physician global assessment of disease activity and BASDAI were evaluated at week 0 and 12
Summary
With TNF-blockers availability for spondyloarthritis (SpA), evaluation of new drugs requires quick “go/no go” signals in small scale, short term proof-of-concept (PoC) trials. Biomarkers complementing clinical evaluations may help reducing length and size of these PoCs. We aimed to identify and validate serum biomarkers to predict clinical response at group level in these trials. Response Mean (SRM), reflecting the predictive value at the group level, was high for calprotectin (SRM=1.259). Linear regression revealed low correlations of changes in hs-CRP (r2 between 0.24 and 0.36) and calprotectin (r2 between 0.08 and 0.19) at week 2 with clinical outcome parameters at week 12
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
